Group 1 - The company Shanghai Laishi (SZ 002252) announced that several executives, including the vice chairman and general manager, plan to increase their shareholding by at least 6 million RMB within six months using self-raised funds [1] - As of the first half of 2025, the company's revenue composition shows that blood product production and sales account for 99.21%, while testing equipment and reagents account for 0.76%, and other businesses account for 0.03% [1] - The current market capitalization of Shanghai Laishi is 44.9 billion RMB [1]

格隆汇9月4日丨上海莱士(002252.SZ)公布，副董事长兼总经理JunXu（徐俊）先生、副总经理沈积慧先 生、副总经理陆晖先生、副总经理兼董事会秘书刘峥先生、副总经理宋正敏女士、财务负责人陈乐奇先 生、副总经理黄勤兵先生计划自本公告披露之日起6个月内增持公司股份，拟增持金额合计不低于人民 币600万元，增持所需的资金来源为自筹资金。 ...

Core Viewpoint - The management team of Shanghai Laishi Blood Products Co., Ltd. plans to increase their shareholding in the company, demonstrating confidence in the company's strategic development and long-term investment value, with a total planned investment of no less than RMB 6 million within six months [2][3]. Group 1: Shareholding Increase Plan - The increase in shareholding will be executed through centralized bidding, funded by self-raised capital [2][3]. - The management team members involved in the shareholding increase include Jun Xu, Shen Jihui, Lu Hui, Liu Zheng, Song Zhengmin, Chen Leqi, and Huang Qinbing, with their current shareholdings detailed in a table [2][3]. - The total number of shares held by the management team members, excluding those from the first employee stock ownership plan, is specified [2][3]. Group 2: Employee Stock Ownership Plan - As of the announcement date, the management team members hold remaining shares corresponding to the first employee stock ownership plan, which will only be realized upon meeting specific unlocking conditions [3]. - The management team has previously sold shares obtained from the first employee stock ownership plan after the lock-up period [3]. Group 3: Implementation Conditions - The shareholding increase plan will be executed based on a reasonable assessment of the company's stock value, and the implementation may be postponed if the stock is suspended or if market conditions change [4]. - The management team commits to not reducing their shareholdings during the implementation period and will adhere to relevant laws and regulations [4].

关于公司部分董事及全体高级管理人员增持股份计划的公告 信息披露义务人公司副董事长兼总经理 Jun Xu（徐俊）先生、副总经理沈 积慧先生、副总经理陆晖先生、副总经理兼董事会秘书刘峥先生、副总经理宋正 敏女士、财务负责人陈乐奇先生、副总经理黄勤兵先生保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证券代码：002252 证券简称：上海莱士 公告编号：2025-062 上海莱士血液制品股份有限公司 1、上海莱士血液制品股份有限公司（"公司"）副董事长兼总经理 Jun Xu（徐 俊）先生、副总经理沈积慧先生、副总经理陆晖先生、副总经理兼董事会秘书刘 峥先生、副总经理宋正敏女士、财务负责人陈乐奇先生、副总经理黄勤兵先生计 划自本公告披露之日起 6 个月内增持公司股份，拟增持金额合计不低于人民币 600 万元，增持所需的资金来源为自筹资金。 2、本次增持计划不设置增持股份价格区间，增持人将基于对公司股票价值 的合理判断，择机实施本次增持计划。 公司于 2025 年 9 月 4 日收到副董事长兼总经理 Ju ...

Group 1 - The company announced that its Vice Chairman and General Manager, Jun Xu, along with six other senior management personnel, plan to increase their shareholding in the company [1] - The total amount of the planned share purchase is no less than 6 million RMB, funded by self-raised capital [1] - There is no price range set for this share purchase plan, and if trading is suspended during the implementation period, the plan will be postponed until after trading resumes [1]

Core Viewpoint - The A-share market continues to rise, leading to a prosperous season for brokerage firms, with significant growth in their performance driven by proprietary trading income [2][3]. Group 1: Brokerage Performance - In the first half of the year, 42 listed brokerages achieved a total operating income of 251.87 billion yuan and a net profit of 104.02 billion yuan, representing year-on-year growth of 11.37% and 65.08% respectively [2]. - Proprietary trading contributed significantly to the performance, with total proprietary income reaching 112.35 billion yuan, a year-on-year increase of 53.53%, accounting for over 40% of total income [3][4]. - Among the brokerages, CITIC Securities was the only firm with proprietary income exceeding 10 billion yuan, totaling 19.05 billion yuan, contributing approximately 57% to its total revenue [3]. Group 2: Top Holdings and Stock Preferences - As of the end of June, the top three stocks held by brokerages were Jiangsu Bank, Yong'an Futures, and CITIC Construction Investment, with holdings of 923 million shares, 439 million shares, and 383 million shares respectively [9]. - The market value of these holdings was over 10 billion yuan for Jiangsu Bank alone, indicating strong interest from brokerages in non-bank financials, electronics, and biomedicine sectors [2][9]. - In the second quarter, brokerages significantly increased their positions in stocks like Sichuan Chengyu and Hongchuang Holdings, with notable increases in shareholdings [11]. Group 3: Changes in Holdings - Brokerages reduced their holdings in several stocks, including Huangshi Group and Shanghai Mechanical, with significant decreases in share quantities [12][16]. - The reduction in holdings was particularly pronounced for Huangshi Group, where Oriental Securities cut its stake by over 34% due to regulatory issues [15]. - Other stocks that saw substantial reductions included New Steel and Yingfang Micro, with brokerages decreasing their holdings by over 2 million shares in the second quarter [16].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引第9号一一回购股份》等相 关法律、法规的规定，上市公司回购股份占上市公司总股本的比例每增加1%的，应当自该事实发生之 日起三个交易日内予以公告；公司应当在每个月的前三个交易日内披露截至上月末的回购进展情况。现 将回购情况公告如下： 一、回购股份的进展情况 截至2025年8月29日，公司通过股份回购专用证券账户以集中竞价方式累计回购公司股份68,321,952股， 占公司总股本的1.03%，最高成交价为7.09元/股，最低成交价为6.62元/股，成交总金额为469,849,037.98 元（不含交易佣金等交易费用）。 上述回购符合公司既定回购股份方案及相关法律法规的要求。 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托时段均符合《深圳证券交易 所上市公司自律监管指引第9号一一回购股份》的相关规定，包括： 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及 ...

Group 1 - The core point of the article is that Shanghai Laishi (002252) announced a share buyback program, having repurchased a total of 68,321,952 shares, which represents 1.03% of the company's total share capital, as of August 29, 2025 [1]

上海莱士9月2日公告，经审议同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股 份，用于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于2.5亿元（含）且不超过5亿元 （含），拟回购股份价格不超过9.55元/股（含），具体回购股份数量以回购股份方案实施完毕或回购 实施期限届满时实际回购情况为准。截至2025年8月29日，公司累计回购6832.2万股，占公司总股本的 1.03％，回购价格区间为6.62元/股至7.09元/股，累计使用资金4.7亿元（不含交易佣金等交易费用）。 ...

Group 1 - The company Shanghai Laishi (002252.SZ) announced a share buyback program, having repurchased a total of 68,321,952 shares, which represents 1.03% of its total share capital [1] - The highest transaction price during the buyback was 7.09 CNY per share, while the lowest was 6.62 CNY per share [1] - The total amount spent on the share buyback reached 469.8 million CNY, excluding transaction commissions and other fees [1]